Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/ paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Molife, L Rhoda ^a   Yan, Li ^b   Vitfell Rasmussen, Joanna ^a   Zernhelt, Adriane M ^b   Sullivan, Daniel M ^c   Cassier, Philippe A ^a,g   Chen, Eric ^d   Biondo, Andrea ^a   Tetteh, Ernestina ^b   Siu, Lillian L ^d   Patnaik, Amita ^e   Papadopoulos, Kyriakos P ^e   De Bono, Johann S ^a,f   Tolcher, Anthony W ^e   Minton, Susan ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e South Texas Accelerated Research Therapeutics (START)   (United States)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g CENTRE LÉON BÉRARD   (France)

Author keywords

AKT inhibitor; Chemotherapy; Combination therapy; MK 2206; Phase 1; Protein serine threonine kinase; Solid tumors

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; ERLOTINIB; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLON TUMOR; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ESOPHAGUS TUMOR; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE CANCER; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS TUMOR; PAROTID GLAND TUMOR; PHASE 1 CLINICAL TRIAL; PROSTATE TUMOR; PRURITUS; RASH; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; UTERINE CERVIX CANCER; VOMITING; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; STOMATITIS; TAXOIDS; TINNITUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892184505     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-1     Document Type: Article

References (30)

1. The PKB/AKT pathway in cancer. Carnero A, Curr Pharm Des 2010 16 34 44 10.2174/138161210789941865 20214616
2. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH, Cancer Res 2007 67 6325 6332 10.1158/0008-5472.CAN-06-4261 17616691
3. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. West KA, Castillo SS, Dennis PA, Drug Resist Updat 2002 5 234 248 10.1016/S1368-7646(02)00120-6 12531180
4. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Engelman JA, Nat Rev Cancer 2009 9 550 562 10.1038/nrc2664 19629070
5. The PI3K pathway as drug target in human cancer. Courtney KD, Corcoran RB, Engelman JA, J Clin Oncol 2010 28 1075 1083 10.1200/JCO.2009.25.3641 20085938
6. Targeted cancer therapies. Yan L, Rosen N, Arteaga C, Chin J Cancer 2011 30 1 4 10.5732/cjc.010.10553 21192839
7. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Yap TA, Garrett MD, Walton MI, Raynaud F, De Bono JS, Workman P, Curr Opin Pharmacol 2008 8 393 412 10.1016/j.coph.2008.08.004 18721898
8. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN, Cell 1995 81 727 736 10.1016/0092-8674(95)90534-0 7774014
9. PKB/AKT: functional insights from genetic models. Scheid MP, Woodgett JR, Nat Rev Mol Cell Biol 2001 2 760 768 10.1038/35096067 11584303
10. AKT signaling in normal and malignant cells. Testa JR, Tsichlis PN, Oncogene 2005 24 7391 7393 10.1038/sj.onc.1209100 16288285
11. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS, J Cell Biol 2005 171 1023 1034 10.1083/jcb.200505087 16365168
12. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Winograd-Katz SE, Levitzki A, Oncogene 2006 25 7381 7390 10.1038/sj.onc.1209737 16785992
13. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Brognard J, Clark AS, Ni Y, Dennis PA, Cancer Res 2001 61 3986 3997 11358816
14. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Clark AS, West K, Streicher S, Dennis PA, Mol Cancer Ther 2002 1 707 717 12479367
15. Inhibitor hijacking of Akt activation. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM, Nat Chem Biol 2009 5 484 493 10.1038/nchembio.183 19465931
16. A potent allosteric AKT inhibitor. Yan L, AACR 2009 abstract DDT01-1
17. Phase 1 clincial trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (OW) dose regimen in patients with advanced solid tumors. Biondo A, Yap TA, Yan L, Patnaik A, Fearen I, Baird RD, Papadopoulos KP, Delgado LM, Taylor A, Lupinacci L, et al. J Clin Oncol 2011 29 3037 10.1200/JCO.2010.33.8038 21709185
18. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, et al. J Clin Oncol 2011 29 4688 4695 10.1200/JCO.2011.35.5263 22025163
19. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al. Mol Cancer Ther 2010 9 1956 1967 10.1158/1535-7163.MCT-09-1012 20571069
20. Dose-finding in phase I clinical trials based on toxicity probability intervals. Ji Y, Li Y, Nebiyou BB, Clin Trials 2007 4 235 244 10.1177/1740774507079442 17715248
21. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. Perkins G, Yap TA, Pope L, et al. PLoS One 2012 7 11 47020 10.1371/journal.pone.0047020 23144797
22. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, et al. J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
23. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA, Clin Cancer Res 2004 10 1976 1983 10.1158/1078-0432.CCR-0842-03 15041715
24. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. Ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD, J Clin Oncol 2005 23 1070 1077 10.1200/JCO.2005.03.082 15718305
25. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Van Zuylen L, Sparreboom A, Van der GA, van der Burg ME, Van BV, Bol CJ, Woestenborghs R, Palmer PA, Verweij J, Clin Cancer Res 2000 6 1365 1371 10778964
26. Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). Mack C, Farneth N, Mahaffey C, Lara P, Gandara DR, J Clin Oncol 2011 29 7573
27. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, et al. Nat Med 2008 14 1351 1356 10.1038/nm.1890 19029981
28. A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. Tolcher AW, Baird RD, Patnaik A, Moreno Garcia V, Papadopoulos KP, Garrett CR, Olmos D, Shannon KA, Zazulina V, Eubin EH, Smith IC, Ryan J, Smith PD, Taylor A, Learoyd M, Lupinacci L, Yan L, De Bono JS, J Clin Oncol 2011 29 3004
29. The BATTLE trial: personalizing therapy for lung cancer. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, et al. Cancer Discov 2011 1 44 53 10.1158/2159-8274.CD- 10-0010 22586319
30. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Sarker D, Reid AH, Yap TA, De Bono JS, Clin Cancer Res 2009 15 4799 4805 10.1158/1078-0432.CCR-08-0125 19638457